• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
TRIL

TRIL

Trillion Dollar Club Index ETF

NASDAQFinancial ServicesAsset ManagementUS

USD19.86

+0.07 (+0.37%)

Company Profile

IPO Date

2025-09-30

Sector

Financial Services

Industry

Asset Management

Exchange

NASDAQ

Country

US

Market Metrics

Open

$19.83

Prev. Close

$19.79

Day Low

$19.83

Day High

$19.90

52W Low

$19.23

52W High

$21.27

Market Cap

$0.00B

Volume

0.00M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

30.5%

Avg Negative

2.1%

Avg Neutral

67.2%

News Feed

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine and Venetoclax in TP53-Wild Type Acute Myeloid Leukemia

GlobeNewsWire·7/6/2021·↑ positive

Trillium Therapeutics Joins Russell 2000® and 3000® Indices

GlobeNewsWire·6/25/2021·↑ positive

Trillium Announces Voting Results From the Annual General and Special Meeting of Shareholders

GlobeNewsWire·6/9/2021·↑ positive

Trillium Therapeutics: Recent Data Update Solidifies Its Approach

Seeking Alpha·5/16/2021·↑ positive

Trillium Therapeutics Reports First Quarter 2021 Operating and Financial Results

GlobeNewsWire·5/7/2021·↓ negative

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

GlobeNewsWire·4/28/2021·↑ positive

Trillium Therapeutics Provides Data Update, Announces Phase 1b/2 Program Priorities Across Hematologic Malignancies and Solid Tumors, and Reports Governance Changes

GlobeNewsWire·4/28/2021·↑ positive

Trillium Therapeutics' CD47 Lead Evokes Pfizer's Interest

Seeking Alpha·4/14/2021·↑ positive

Trillium Therapeutics Reports Annual Operating and Financial Results and Sets Date for R&D Day

GlobeNewsWire·3/18/2021·↑ positive

Trillium Therapeutics: A Potentially Undervalued CD47 Player

Seeking Alpha·1/18/2021·↑ positive